Shares of Affymetrix jumped 19 percent Thursday after the Swiss drug firm Roche said it would pay $70 million for a license to use the Santa Clara company's DNA chips to create new ways to diagnose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback